Clinical trials: Idiopathic Aplastic Anemia
Aplastic Anemia, Healthy
Collection of Blood and Bone Marrow From Patients With Aplastic Anemia for Analysis of Adhesion Molecules, Chemokines and Their Receptors
This study is designed to collect bone marrow and/or peripheral blood cells and plasma, for the analysis of adhesion molecules, chemokines and their receptors from newly-diagnosed aplastic anemia patients, and patients treated…
- Trial name
- NCT01680055
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Shandong University
Severe Aplastic Anemia
Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia.
The study is a phase II trial designed to evaluate the efficacy and safety of co-transplantation with bone marrow derived mesenchymal stem cells from related donors in alternative donor transplantation of severe aplastic anemia.
- Trial name
- NCT02247973
- Testing
- mesenchymal stem cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangzhou General Hospital of Guangzhou Military Command
Aplastic Anemia
Ambispective Observational Study to Evaluate the Incidence and Management of Aplastic Anemia in Spain
This is a national, multicenter, ambispective, observational post-authorization study (EPA-SP for its acronym in Spanish) to describe the incidence, clinical management and outcome of aplastic anemia in hospitals throughout Spain.
- Trial name
- IISAPM201701 (NCT04001686)
- Testing
- incidence aplastic anemia
- Where
- Spain
- Volunteers
- 109 people
- Sponsor
- Biogipuzkoa Health Research Institute
Aplastic Anemia and Other Marrow Failure Syndrome
Establishing a Data Base for Aplastic Anemia and Other Marrow Failure Syndrome
Establishing a Data Base for Aplastic Anemia and Other Marrow Failure Syndrome
- Trial name
- NCT01310959
- Testing
- Database
- Where
- Saudi Arabia
- Volunteers
- 88 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Blood Disease, Anemia, Aplastic
Drug Etiology of Aplastic Anemia and Related Dyscrasias
To determine the role of drugs in the etiology of aplastic anemia, agranulocytosis, and thrombocytopenic purpura. Drugs used in chemotherapy and immunotherapy were excluded.
- Conditions
- Blood Disease, Anemia, Aplastic, Agranulocytosis, Purpura, Thrombocytopenic
- Trial name
- NCT00005302
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Severe Aplastic Anemia
Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy
Background: Severe aplastic anemia (SAA) is a form of bone marrow failure. It usually results from a cytotoxic T cell attack on the marrow stem cell. Two treatments can be used for most people with SAA.
- Trial name
- NCT04436380
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Leukemia, Myelodysplastic Syndromes
Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors
Graft-versus-host disease (GVHD) is an important complication after transplantation, with an incidence of 40-60%, which can increase non-relapse mortality if poorly controlled.
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia
- Trial name
- NCT06279494
- Testing
- Sirolimus, Abatacept, MMF
- Volunteers
- 6 people
- Sponsor
- Peking University People's Hospital
Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia
Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.
To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia (ITP) from hypo-proliferative causes of thrombocytopenia.
- Conditions
- Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia, Myelodysplasia, Aplastic Anaemia
- Trial name
- NCT01933035
- Testing
- Immune Thrombocytopenics, Hypo-proliferative thrombocytopenics, Control Population
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Beth Israel Medical Center
Aplastic Anaemia, HSCT
Reduced-dose Conditioning Regimen Containing TBI in HSCT Treating Elderly Patients With Aplastic Anemia
The TBI-containing reduced-dose conditioning regimen was used to treat elderly patients with aplastic anemia who received hematopoietic stem cell transplantation.
- Conditions
- Aplastic Anaemia, HSCT, TBI, Old Age
- Trial name
- NCT06769568
- Testing
- reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Myeloproliferative Disorders, Leukemia
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00053989
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Lymphoma
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00002718
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma, Leukemia
Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation
RATIONALE: Following stem cell transplantation, a major risk is graft-versus-host disease (GVHD). This occurs when donor immune cells that have been infused recognise the host's cells as 'foreign' and attack these cells.
- Conditions
- Lymphoma, Leukemia, Myeloma, Myelodysplastic Syndromes
- Trial name
- ToTem (NCT03836690)
- Testing
- CD62L- Tem
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University College, London
Bone Marrow Failure Syndromes, Aplastic Anemias
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes
This is a multicenter, open-label, Phase 1/2 basket study to evaluate the safety and efficacy of Dibotatug (DR-01) in adults with Bone Marrow Failure syndromes.
- Conditions
- Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse
- Trial name
- BMF (NCT07712562)
- Testing
- Dibotatug (DR-01)
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dren Bio
Aplastic Anemia
Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia
Primary Objectives: 1. To determine the feasibility and toxicity of employing purine-analog based conditioning for allogeneic donor stem cell transplantation in patients with severe aplastic anemia (AA). 2.
- Trial name
- NCT00427336
- Testing
- Fludarabine, Cyclophosphamide, Antithymocyte Globulin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Bone Marrow Transplant (BMT)
HPC Offered for PRESERVE Expansion
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons.
- Trial name
- HOPE (NCT07145411)
- Testing
- Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Ossium Health, Inc.
Anemia, Aplastic Anemia
Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study
This pilot study evaluates safety of administration of red blood cell transfusions requested by patients based on their symptoms instead of levels of hemoglobin for the treatment of chronic anemia in patients with blood disorders.
- Conditions
- Anemia, Aplastic Anemia, Bone Marrow Failure, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT03086252
- Testing
- Red Blood Cell Transfusions (RBCT)
- Where
- United States
- Sponsor
- Emory University
Aplastic Anemia
Romiplostim N01 in Chemoradiotherapy-induced Aplastic Anemia
This study aimed to explore the efficacy and safety of romiplostim N01 in the treatment of chemoradiotherapy-induced aplastic anemia (AA)
- Trial name
- NCT07572084
- Testing
- Romiplostim N01
- Volunteers
- 43 people
- Sponsor
- Peking Union Medical College Hospital
Aplastic Anemia, Myelodysplastic Syndromes
Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients
To investigate the efficacy of posaconazole as prophylaxis antifungal agent in aplastic anemia / hypoplastic myelodysplastic syndrome (AA/hMDS) patients undergoing antithymocyte globulin (ATG) treatment
- Conditions
- Aplastic Anemia, Myelodysplastic Syndromes, Fungal Infection
- Trial name
- NCT03318159
- Testing
- Posaconazole
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
Bone Marrow Failure Disorders, Aplastic Anemia
TPO-Mimetic Use in Children for Hematopoietic Failure
This is an open label, prospective Pilot interventional study will investigate the safety and efficacy of Romiplostim, thrombopoietin (TPO) mimetic, in children (ages: 0 to 21 years) with broad scope of bone marrow failure…
- Conditions
- Bone Marrow Failure Disorders, Aplastic Anemia, Thrombocytopenia, Refractory Cytopenia of Childhood
- Trial name
- NCT04478227
- Testing
- Romiplostim
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Anjali Sharathkumar
Aplastic Anemia
ATGAM General Investigation
The objective of this study is to confirm the safety of ATGAM in patients with moderate to severe aplastic anemia under the actual use in Japan.
- Trial name
- NCT06039020
- Testing
- Anti-human thymocyte immunoglobulin, equine
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Pfizer